ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.
Company profile
Ticker
ASND
Exchange
Website
CEO
Jan Moeller Mikkelsen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ASND stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
10 Apr 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
14 Mar 24
S-8
Registration of securities for employees
29 Feb 24
6-K
Current report (foreign)
29 Feb 24
6-K
Current report (foreign)
14 Feb 24
20-F
2023 FY
Annual report (foreign)
7 Feb 24
6-K
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
7 Feb 24
6-K
Current report (foreign)
31 Jan 24
6-K
Current report (foreign)
29 Jan 24
Transcripts
ASND
Earnings call transcript
2023 Q1
27 Apr 23
ASND
Earnings call transcript
2022 Q4
16 Feb 23
ASND
Earnings call transcript
2022 Q3
5 Nov 22
ASND
Earnings call transcript
2022 Q2
11 Aug 22
ASND
Earnings call transcript
2022 Q1
12 May 22
ASND
Earnings call transcript
2021 Q4
3 Mar 22
ASND
Earnings call transcript
2021 Q2
26 Aug 21
ASND
Earnings call transcript
2021 Q1
28 May 21
ASND
Earnings call transcript
2020 Q4
11 Mar 21
ASND
Earnings call transcript
2020 Q3
11 Nov 20
Latest ownership filings
144
Notice of proposed sale of securities
7 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
News
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
18 Apr 24
Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target
18 Apr 24
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
3 Apr 24
JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $167
2 Apr 24
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
15 Mar 24
Press releases
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
4 Mar 24
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
7 Feb 24
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
31 Jan 24
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
31 Jan 24